Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subcutaneous Vedolizumab in Healthy Volunteers
NCT02163421Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vedolizumab in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Takeda. Primary endpoint: Population Mean Estimate for Bioavailability Following Subcutaneous (SC) Administration at Day 127. Started Jun 2014; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02163421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163421.